Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Rampart Bioscience logo — Leading a new era of effective, safe and accessible gene med...

Rampart Bioscience

Leading a new era of effective, safe and accessible gene medicines.

Founded 2019 United States Monrovia, United States 28 employees Series A Total: $125.00M Biopharma, Biotechnology +1

General Information

Company Name Rampart Bioscience
Founded Year 2019
Location United States Monrovia, United States
Employees 28
Industries Biopharma, Biotechnology, Health and Wellness
Funding Stage Series A
Business Model B2B, B2D
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Rampart Bioscience. To contact Rampart Bioscience, visit rampartbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Rampart Bioscience compare?

A PDF of Rampart Bioscience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Rampart Bioscience soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Rampart Bioscience

Rampart Bioscience, founded in 2019, is pioneering advancements in the Biopharma and Biotechnology industries. Based in the United States, the company aims to lead a new era of effective, safe, and accessible gene medicines, targeting patients with genetically driven diseases. Its innovative approach integrates capabilities from gene delivery, protein sciences, and clinical translation to surpass the current limitations of gene therapies.

The key differentiator for Rampart Bioscience lies in its novel non-viral DNA delivery system, which aspires to achieve higher standards of potency, durability, redosability, and safety. Such innovations are set to reshape the treatment landscape and present new opportunities for addressing unmet medical needs.

In the most recent funding round—an $85.00M Series A investment in October 2023—the company garnered the support of prominent investors like RA Capital Management, HealthCap, OrbiMed, and Forbion Capital Partners, underscoring strong market confidence in its potential.

Business keywords: gene medicines, genetically driven diseases, gene delivery, protein sciences, clinical translation, non-viral DNA delivery, therapeutic optimization, potency enhancement, durability of treatment, redosability, safety in gene therapies, proprietary development platforms, non-viral therapeutics, biotechnology innovation, disease treatment reshaping

Services & Products

Development of Novel DNA-Based Medicines
Research in Gene Delivery and Protein Sciences
Non-Viral DNA Delivery Systems

Target Customers

Patients with Genetically Driven Diseases Healthcare Providers Seeking Advanced Therapies

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $85.00M 4
RA Capital Management HealthCap OrbiMed
RA Capital Management, HealthCap +2
01 Oct 2023
Seed $40.00M 1
OrbiMed
OrbiMed
01 Jan 2022

Rampart Bioscience Alternatives & Competitors

View All Alternatives
Rampart Bioscience vs
ReNAgade Therapeutics
ReNAgade Therapeutics United States

RNA Without Limits

Series A
24 employees
Biotechnology, Health and Wellness
Compare Rampart Bioscience vs ReNAgade Therapeutics
Rampart Bioscience vs
Basilard BioTech, Inc.
Basilard BioTech, Inc. United States

Nanomechanical Gene Delivery to Transform the Engineering of Cell Based Therapies

Seed
5 employees
Biopharma, Biotechnology
Compare Rampart Bioscience vs Basilard BioTech, Inc.
Rampart Bioscience vs
BIORCHESTRA Co., Ltd.
BIORCHESTRA Co., Ltd. United States

We develop novel RNA-based therapeutics that will be able to bring about a paradigm shift for neurod...

Series C
17 employees
Biopharma, Biotechnology
Also compare with: Rampart Bioscience vs ViaNautis ViaNautis View all alternatives

FAQ About Rampart Bioscience

Leading a new era of effective, safe and accessible gene medicines.
Rampart Bioscience was founded in 2019.
Rampart Bioscience is headquartered in Monrovia, United States.
Rampart Bioscience operates in Biopharma, Biotechnology and Health and Wellness. Its work centres on gene medicines, genetically driven diseases, gene delivery and protein sciences. Its customers include Patients with Genetically Driven Diseases and Healthcare Providers Seeking Advanced Therapies.
Rampart Bioscience has a B2B and B2D business model. Its revenue comes from Licensing, Product Sales and Service Fee.
Rampart Bioscience has approximately 28 employees.
Rampart Bioscience has completed 2 funding rounds, raising a total of $125.00M. The latest funding stage is Series A.
Rampart Bioscience offers: Development of Novel DNA-Based Medicines, Research in Gene Delivery and Protein Sciences, Non-Viral DNA Delivery Systems.
Top alternatives and competitors to Rampart Bioscience include ReNAgade Therapeutics, Basilard BioTech, Inc., BIORCHESTRA Co., Ltd., BreezeBio, Ring Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Rampart Bioscience and ReNAgade Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Rampart Bioscience, https://bouncewatch.com/company/rampart-bioscience, updated 19 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout